Amicus Therapeutics secures $430M from Blackstone in financing agreement

Amicus Therapeutics announced Tuesday that it has entered into a definitive agreement with Blackstone for a $430 million financing collaboration.

As part of the agreement, Blackstone is providing the biotech with a $400 million senior secured term loan facility as well as a $30 million investment in Amicus common stock.